For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- ARB + CCB Combination Drugs Ranked in Top Positions in HP, GP Markets: RepTrack Survey
February 28, 2011
- WT1 mRNA Assay Kit Otsuka Approved for MDS
February 28, 2011
- New Drugs Improve Range of Options for Osteoporosis: 2
February 28, 2011
- Eisai Ties Up with Teikoku Seiyaku for Transdermal Aricept Formulation in Japan
February 21, 2011
- Importance of Close Links between Clinical Trials, Studies Highlighted at Gene Therapy Symposium
February 21, 2011
- Medipal Aims at Sales of ¥3 Tril. in FY2013
February 21, 2011
- Look at New Trends in Emerging Countries: Mr Hasegawa
February 21, 2011
- Price Settlement Rate Down to Levels before Emergency Call
February 21, 2011
- Takeda Begins PIII Trial of Alogliptin in China
February 21, 2011
- New Drugs Improve Range of Options for Osteoporosis: 1
February 21, 2011
- Korosho to Carry Out Case Studies to Promote Use of Generics
February 21, 2011
- Janssen Launches Once-Daily Fentanyl Patch
February 21, 2011
- No Differences in Impurity Contents in 6 Cisplatin Products: NIHS Study Group
February 21, 2011
- Astellas Licenses Fidaxomicin from Optimer
February 21, 2011
- Sawai: First 3-Qtr Sales, Profits Show Double-Digit Growth
February 21, 2011
- Astellas Creates Sales Subsidiary in Australia
February 21, 2011
- PHARMA JAPAN Lexicon: 47
February 21, 2011
- Santen Allies with DBJ
February 21, 2011
- Korosho to Review Current Risk Classification of OTC Drugs
February 21, 2011
- Otsuka Holds Sufficient Stock of IFN from Hayashibara
February 21, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…